JP2019019113A - Orally disintegrating tablet containing memantine hydrochloride - Google Patents

Orally disintegrating tablet containing memantine hydrochloride Download PDF

Info

Publication number
JP2019019113A
JP2019019113A JP2017147187A JP2017147187A JP2019019113A JP 2019019113 A JP2019019113 A JP 2019019113A JP 2017147187 A JP2017147187 A JP 2017147187A JP 2017147187 A JP2017147187 A JP 2017147187A JP 2019019113 A JP2019019113 A JP 2019019113A
Authority
JP
Japan
Prior art keywords
memantine hydrochloride
orally disintegrating
tablet
disintegrating tablet
hardness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017147187A
Other languages
Japanese (ja)
Other versions
JP7198575B2 (en
Inventor
将孝 前田
Masataka Maeda
将孝 前田
崇 菅原
Takashi Sugawara
崇 菅原
佳典 森下
Yoshinori Morishita
佳典 森下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Rimedio Co Ltd
Original Assignee
Kyorin Rimedio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Rimedio Co Ltd filed Critical Kyorin Rimedio Co Ltd
Priority to JP2017147187A priority Critical patent/JP7198575B2/en
Publication of JP2019019113A publication Critical patent/JP2019019113A/en
Application granted granted Critical
Publication of JP7198575B2 publication Critical patent/JP7198575B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

To provide an orally disintegrating tablet containing memantine hydrochloride which has both appropriate hardness and quick disintegrability in an oral cavity, and has small reduction of hardness over time due to humidified storage, and by which excellent oral disintegrability is maintained.SOLUTION: According to the present invention, there is provided an orally disintegrating tablet containing memantine hydrochloride which contains powder of memantine hydrochloride or particles containing memantine hydrochloride, and low-substituted hydroxypropyl cellulose. Further, according to the present invention, the orally disintegrating tablet quickly disintegrates when included into mouth or put into water, and is equipped with excellent hardness and excellent oral disintegrability even after storage under a humidified condition.SELECTED DRAWING: None

Description

本発明は、少量の水又は水なしで服用しても口腔内で速やかに崩壊するメマンチン塩酸塩含有口腔内崩壊錠及びその製造方法に関する。特に、加湿条件下に保存しても錠剤の硬度低下が少なく、かつ良好な口腔内崩壊性を維持するメマンチン塩酸塩含有口腔内崩壊錠及びその製造方法に関する。  The present invention relates to a memantine hydrochloride-containing orally disintegrating tablet that rapidly disintegrates in the oral cavity even if it is taken with a small amount of water or without water, and a method for producing the same. In particular, the present invention relates to a memantine hydrochloride-containing orally disintegrating tablet that maintains little orally disintegrating property even when stored under humidified conditions, and a method for producing the same.

メマンチン(1‐アミノ‐3,5‐ジメチルアダマンタン)は強い電位依存性及び速い遮断/非遮断動力性を有し、中等度及び高度アルツハイマー型認知症症状の進行を抑制する非競合NMDA受容体遮断薬である。  Memantine (1-amino-3,5-dimethyladamantane) has strong voltage dependence and fast blocking / non-blocking kinetics, non-competitive NMDA receptor blockade that suppresses the progression of moderate and severe Alzheimer's dementia symptoms It is a medicine.

中等度及び高度アルツハイマー型認知症状の進行を抑制する治療薬であるメマンチン塩酸塩は、現在、フィルムコーティング錠及び口腔内崩壊錠として市販されている(非特許文献1)。  Memantine hydrochloride, a therapeutic agent that suppresses the progression of moderate and severe Alzheimer-type cognitive symptoms, is currently marketed as a film-coated tablet and an orally disintegrating tablet (Non-patent Document 1).

中等度及び高度アルツハイマー型認知症は高齢者の患者が大半であり、嚥下力が低下している場合があるため、口腔内で速やかに崩壊し、口腔内の唾液や少量の水で服用可能な口腔内崩壊錠を剤型とするメマンチン塩酸塩製剤が提案されている。例えば、特許文献1には、微晶質セルロースが20重量%から95重量%の範囲で存在する即効型経口固形投与形が記載されている。  Moderate and severe Alzheimer's dementia is mostly elderly and may have reduced swallowing power, so it can quickly disintegrate in the oral cavity and be taken with oral saliva or small amounts of water A memantine hydrochloride formulation having an orally disintegrating tablet as a dosage form has been proposed. For example, Patent Document 1 describes an immediate-acting oral solid dosage form in which microcrystalline cellulose is present in the range of 20% to 95% by weight.

また、特許文献2には、かさ密度が0.23g/cm以下の結晶セルロース、糖アルコール及びアルファー化デンプンを含有する口腔内崩壊錠が記載されている。Patent Document 2 describes an orally disintegrating tablet containing crystalline cellulose having a bulk density of 0.23 g / cm 3 or less, a sugar alcohol, and pregelatinized starch.

口腔内崩壊錠は、水なしで服用しても口腔内で速やかに崩壊する錠剤であり、嚥下機能が低下した高齢者にも服用しやすい製剤である。近年、病院や調剤薬局では患者が複数の薬を服用する場合には、患者が薬を飲み忘れたり、飲み違えたりするのを防ぐために、服用する時間帯ごとに複数の薬を一つの簡易の小袋に納める一包化による服薬コンプライアンス改善の取り組みが盛んとなっている。この一包化の際に、調剤ミスの防止や調剤業務の効率化を目的に自動錠剤分包機が用いられる。このため、薬局での一包化の作業時から患者が薬を服用するまでの間に、防湿等の効果を有する本来のパッケージやPTPシートから薬剤が取り出され、加湿条件下に曝露される。特に、口腔内崩壊錠は、一般的に口腔内で容易に崩壊するように設計されているため、通常の錠剤よりも硬度が低く、加湿条件下に曝露されると、経時的に錠剤の硬度が低下し、服用前に錠剤が破損したり、口腔内崩壊時間が変動したりする恐れがある。また、錠剤硬度が低下すると、錠剤自動分包機による一包化の際の衝撃で、錠剤が破損する危険性もある。このため、医療現場では、加湿条件下で保存しても錠剤の硬度低下が小さく、崩壊性が維持され、更には自動分包による一包化にも破損が生じない口腔内崩壊錠の開発が望まれている。  Orally disintegrating tablets are tablets that disintegrate rapidly in the oral cavity even when taken without water, and are easy to take even for elderly people with reduced swallowing function. In recent years, when patients take multiple drugs at hospitals and dispensing pharmacies, to prevent patients from forgetting to take drugs or taking them wrongly, multiple simple drugs are taken for each time period. Efforts to improve medication compliance by packaging into small bags are thriving. An automatic tablet packaging machine is used for the purpose of preventing the dispensing mistake and improving the efficiency of the dispensing operation. For this reason, the medicine is taken out from the original package or PTP sheet having an effect of moisture prevention or the like and exposed to the humidified condition from the time of encapsulating in the pharmacy until the patient takes the medicine. In particular, orally disintegrating tablets are generally designed to disintegrate easily in the oral cavity, and therefore have a lower hardness than ordinary tablets, and when exposed to humid conditions, the hardness of the tablets over time There is a risk that the tablet will be damaged before taking or the disintegration time in the oral cavity may fluctuate. Moreover, when tablet hardness falls, there exists a danger that a tablet may be damaged by the impact at the time of the packaging by the tablet automatic packaging machine. For this reason, the development of orally disintegrating tablets has been developed in the medical field, where the decrease in tablet hardness is small even when stored under humidified conditions, the disintegration property is maintained, and further, there is no breakage even in packaging by automatic packaging. It is desired.

特許文献1は、薬物放出性と生体内吸収性に優れる即効型経口固形投与形態を提供することを目的としているものであり、良好な口腔内崩壊性であること、さらに加湿条件下での保存後でも良好な硬度や良好な口腔内崩壊性を兼ね備えているという課題及び解決手段を示唆しているものではない。  Patent Document 1 is intended to provide an immediate-acting oral solid dosage form that is excellent in drug release and in vivo absorption, has good oral disintegration, and is stored under humidified conditions. There is no suggestion of a problem and a solution that both have good hardness and good disintegration properties in the oral cavity.

特許文献2には、良好な口腔内崩壊性および十分な硬度を有した口腔内崩壊錠が記載されている。しかしながら、加湿条件下での保存後でも良好な硬度や良好な口腔内崩壊性を有しているという課題及び解決手段を示唆しているものではない。  Patent Document 2 describes an orally disintegrating tablet having good orally disintegrating property and sufficient hardness. However, it does not suggest the problem and solution means that it has good hardness and good oral disintegration even after storage under humidified conditions.

非特許文献1には、メマンチン塩酸塩を含む市販の口腔内崩壊錠について、錠剤自動分包機による一包化が可能であるものの、湿気を避けて保存する必要があることや吸湿により錠剤表面がざらつく等の注意が記載されている。  Non-Patent Document 1 discloses that a commercially available orally disintegrating tablet containing memantine hydrochloride can be packaged by a tablet automatic packaging machine, but it must be stored away from moisture, and the tablet surface may be absorbed by moisture absorption. Precautions such as roughness are described.

特表2008−509089号公報Special table 2008-509089 特開2017−008112号公報Japanese Unexamined Patent Publication No. 2017-008112

医薬品インタビューフォーム メマリーOD錠 2016年8月改定(第11版)Drug Interview Form Memary OD Tablet Revised August 2016 (11th Edition) 「錠剤・カプセル剤の無包装状態での安定性情報に関する調査研究」日本病院薬剤師会雑誌、35,176−182(1999)“Investigative study on stability information of tablets and capsules in non-packaging”, Journal of the Japan Hospital Pharmacists Association, 35, 176-182 (1999)

従って、本発明は、適度な硬度と口腔内での速やかな崩壊性を兼ね備え、かつ加湿保存による経時的な硬度低下が小さく、加湿保存後も良好な硬度と良好な口腔内崩壊性が維持される、ユーザービリティに優れたメマンチン塩酸塩含有口腔内崩壊錠およびその製造方法を提供することを課題とする。  Therefore, the present invention has an appropriate hardness and rapid disintegration in the oral cavity, and the decrease in hardness over time due to humid storage is small, and good hardness and good oral disintegration are maintained even after humid storage. Another object of the present invention is to provide a memantine hydrochloride-containing orally disintegrating tablet excellent in usability and a method for producing the same.

本発明者らは、上記課題を解決すべく鋭意検討した結果、メマンチン塩酸塩の粉末またはメマンチン塩酸塩を含有する顆粒に、低置換度ヒドロキシプロピルセルロースを添加し圧縮成型することで、適度な硬度と口腔内での速やかな崩壊性を兼ね備え、従来より知られていた市販の口腔内崩壊錠等に比して、加湿保存による経時的な硬度低下が小さく、加湿保存後も良好な硬度と良好な口腔内崩壊性を維持するメマンチン塩酸塩含有口腔内崩壊錠を見出し、本発明を完成させた。  As a result of intensive studies to solve the above problems, the present inventors have added low-substituted hydroxypropylcellulose to a granule containing memantine hydrochloride or memantine hydrochloride and compression-molded to obtain an appropriate hardness. In addition, it has a rapid disintegration property in the oral cavity, and compared with the conventionally known commercially available orally disintegrating tablets, the decrease in hardness over time due to humid storage is small, and good hardness and good after humid storage The present invention was completed by finding a memantine hydrochloride-containing orally disintegrating tablet that maintains a good orally disintegrating property.

すなわち本発明は、メマンチン塩酸塩の粉末またはメマンチン塩酸塩を含有する顆粒に低置換度ヒドロキシプロピルセルロースを混合し圧縮成型することを特徴とする口腔内崩壊錠及びその製造方法を提供するものである。  That is, the present invention provides an orally disintegrating tablet characterized in that low-substituted hydroxypropylcellulose is mixed with a powder of memantine hydrochloride or memantine hydrochloride-containing granules and compression-molded, and a method for producing the same. .

すなわち本発明は、以下の発明を含む。
(1)メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含有する顆粒、及び低置換度ヒドロキシプロピルセルロースを含有する、メマンチン塩酸塩含有口腔内崩壊錠。
(2)メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含有する顆粒が、糖アルコールで被覆されている、(1)に記載のメマンチン塩酸塩含有口腔内崩壊錠。
(3)錠剤の全重量に対して、メマンチン塩酸塩の含量が2.0重量%以上10.0重量%以下である、(1)または(2)に記載のメマンチン塩酸塩含有口腔内崩壊錠。
(4)錠剤の全重量に対して、低置換度ヒドロキシプロピルセルロースの含量が0.5重量%以上15.0重量%以下である、(1)から(3)のいずれか1つに記載のメマンチン塩酸塩含有口腔内崩壊錠。
(5)糖アルコールがマンニトールである、(2)から(4)のいずれか1つに記載のメマンチン塩酸塩含有口腔内崩壊錠。
(6)25℃、相対湿度75%に3日間保存後の錠剤硬度が2.0Kgf以上である、(1)から(5)のいずれか1つに記載のメマンチン塩酸塩含有口腔内崩壊錠。
(7)流動層造粒法によって製造することを特徴とする、(1)から(6)のいずれか1つに記載のメマンチン塩酸塩含有口腔内崩壊錠の製造方法。
That is, the present invention includes the following inventions.
(1) A memantine hydrochloride-containing orally disintegrating tablet containing memantine hydrochloride powder or granules containing memantine hydrochloride and low-substituted hydroxypropylcellulose.
(2) The memantine hydrochloride-containing orally disintegrating tablet according to (1), wherein memantine hydrochloride powder or memantine hydrochloride-containing granules are coated with a sugar alcohol.
(3) The memantine hydrochloride-containing orally disintegrating tablet according to (1) or (2), wherein the content of memantine hydrochloride is 2.0% by weight to 10.0% by weight with respect to the total weight of the tablet .
(4) The content of low-substituted hydroxypropylcellulose is 0.5% by weight or more and 15.0% by weight or less with respect to the total weight of the tablet, according to any one of (1) to (3) Memantine hydrochloride-containing orally disintegrating tablets.
(5) The memantine hydrochloride-containing orally disintegrating tablet according to any one of (2) to (4), wherein the sugar alcohol is mannitol.
(6) The memantine hydrochloride-containing orally disintegrating tablet according to any one of (1) to (5), wherein the tablet hardness after storage for 3 days at 25 ° C. and 75% relative humidity is 2.0 kgf or more.
(7) The method for producing a memantine hydrochloride-containing orally disintegrating tablet according to any one of (1) to (6), which is produced by a fluidized bed granulation method.

本発明によると、適度な硬度と口腔内での速やかな崩壊性を兼ね備え、かつ加湿条件下保存における経時的な硬度低下が小さく、加湿条件下保存後も良好な硬度と良好な口腔内崩壊性が維持されるメマンチン塩酸塩含有口腔内崩壊錠が提供される。また、特殊な生産設備を設けることなく、一般的な製造設備にて製造可能な製造方法が提供される。
このため、医療現場や流通過程において加湿条件下に錠剤が曝露された場合でも、良好な硬度と良好な口腔内崩壊性を具備するメマンチン塩酸塩含有口腔内崩壊錠を提供することができる。
According to the present invention, it has moderate hardness and quick disintegration in the oral cavity, and has a small decrease in hardness over time when stored under humidified conditions. Good hardness and good oral disintegration even after storage under humidified conditions. An orally disintegrating tablet containing memantine hydrochloride is provided. Moreover, the manufacturing method which can be manufactured with a general manufacturing facility without providing special production facilities is provided.
Therefore, a memantine hydrochloride-containing orally disintegrating tablet having good hardness and good orally disintegrating property can be provided even when the tablet is exposed under humidified conditions in the medical field or distribution process.

以下、本発明に係るメマンチン塩酸塩含有口腔内崩壊錠について説明する。ただし、本発明のメマンチン塩酸塩含有口腔内崩壊錠は、以下に示す実施の形態及び実施例の記載内容に限定して解釈されるものではない。  Hereinafter, the memantine hydrochloride-containing orally disintegrating tablet according to the present invention will be described. However, the memantine hydrochloride-containing orally disintegrating tablet of the present invention is not construed as being limited to the description of the embodiments and examples shown below.

本発明において、加湿条件下で保存した後の「良好な口腔内崩壊性」とは、温度25℃、湿度75%に3日間、開封状態で保存した口腔内崩壊錠が口腔内の唾液のみ又は少量の水で約20秒前後、もしくはそれ以下の時間で速やかに崩壊することをいう。  In the present invention, “good oral disintegration” after storage under humidified conditions means that the orally disintegrating tablet stored in an opened state at a temperature of 25 ° C. and a humidity of 75% for 3 days is only the saliva in the oral cavity or It means that it quickly disintegrates with a small amount of water in about 20 seconds or less.

本発明において、加湿条件下で保存した後の「良好な硬度」とは、温度25℃、湿度75%に3日間、開封状態で保存した口腔内崩壊錠の硬度が2.0kgf以上となることを意味する(非特許文献2)。  In the present invention, “good hardness” after storage under humidified conditions means that the hardness of an orally disintegrating tablet stored in an opened state at 25 ° C. and 75% humidity for 3 days is 2.0 kgf or more. (Non-Patent Document 2).

本発明者らは、良好な口腔内崩壊性を有し、さらに加湿条件下で保存した後でも良好な硬度と良好な口腔内崩壊性を兼ね備えるメマンチン塩酸塩含有口腔内崩壊錠について検討を行ったところ、メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含む顆粒に低置換度ヒドロキシプロピルセルロースを混合し圧縮成型することで、上記の目的を満たす錠剤が得られることを新たに見出した。  The present inventors examined memantine hydrochloride-containing orally disintegrating tablets that have good orally disintegrating properties and also have good hardness and good orally disintegrating properties even after storage under humidified conditions. However, it has been newly found that tablets satisfying the above-mentioned purpose can be obtained by mixing low-substituted hydroxypropylcellulose with a powder of memantine hydrochloride or granules containing memantine hydrochloride and compression molding.

本発明に係るメマンチン塩酸塩含有口腔内崩壊錠は、メマンチン塩酸塩と低置換度ヒドロキシプロピルセルロースを含有する。本発明において、メマンチン塩酸塩含有口腔内崩壊錠中のメマンチン塩酸塩の含有量は、例えば、5mg/錠、10mg/錠又は20mg/錠である。  The memantine hydrochloride-containing orally disintegrating tablet according to the present invention contains memantine hydrochloride and low-substituted hydroxypropylcellulose. In the present invention, the content of memantine hydrochloride in the memantine hydrochloride-containing orally disintegrating tablet is, for example, 5 mg / tablet, 10 mg / tablet, or 20 mg / tablet.

メマンチン塩酸塩は粉末状のメマンチン塩酸塩として含有されてもよく、また、任意に他の添加剤を含む、顆粒状のメマンチン塩酸塩として含有されてもよい。  Memantine hydrochloride may be contained as powdered memantine hydrochloride or may be contained as granular memantine hydrochloride, optionally containing other additives.

メマンチン塩酸塩は、所望により、粉末状のメマンチン塩酸塩の表面(例えば、メマンチン塩酸塩結晶の表面)または造粒されたメマンチン塩酸塩の顆粒表面をコーティングして用いてもよい。コーティングは薬物由来の不快な味、においや刺激をマスクし服用しやすくなる、光・水・酸素などから薬物を保護し、また、配合変化を起こしやすい成分同士を分離して安定性を向上させる、腸溶化や徐放化により薬物の有効性・安全性を向上させる、などの目的で施され、目的に応じてコーティング方法やコーティング剤が選択される。コーティングは、製剤技術分野において慣用の方法を用いることができ、例えば、流動層造粒・コーティング機、転動流動層造粒・コーティング機、遠心流動型造粒・コーティング機、ワースター型流動層造粒・コーティング機などを用いて行われる。本発明に係るメマンチン塩酸塩の粉末またはメマンチン塩酸塩を含有する顆粒にコーティングする場合、流動層造粒・コーティング機が好ましい。  Memantine hydrochloride may be used by coating the surface of powdered memantine hydrochloride (for example, the surface of memantine hydrochloride crystals) or the granule surface of granulated memantine hydrochloride, if desired. The coating masks the unpleasant taste, smell and irritation caused by the drug, makes it easier to take, protects the drug from light, water, oxygen, etc., and improves stability by separating components that tend to change the formulation. It is applied for the purpose of improving the effectiveness and safety of the drug by enterolysis or sustained release, and a coating method or coating agent is selected according to the purpose. For the coating, a method commonly used in the field of pharmaceutical technology can be used. For example, fluidized bed granulation / coating machine, rolling fluidized bed granulation / coating machine, centrifugal fluidized granulation / coating machine, Wurster type fluidized bed granulator. This is done using a grain / coating machine. When coating on memantine hydrochloride powder or memantine hydrochloride-containing granules according to the present invention, a fluidized bed granulator / coating machine is preferred.

本発明に係る低置換度ヒドロキシプロピルセルロースは、水不溶性添加剤であるため、服用感を考慮して、その配合量はメマンチン塩酸塩含有口腔内崩壊錠に対して0.5重量%以上15.0重量%以下が好ましく、1.0重量%以上5.0重量%以下が特に好ましい。  Since the low-substituted hydroxypropylcellulose according to the present invention is a water-insoluble additive, the blending amount thereof is 0.5% by weight or more and 15.5% or more based on the memantine hydrochloride-containing orally disintegrating tablet in consideration of the ingestion feeling. 0 wt% or less is preferable, and 1.0 wt% or more and 5.0 wt% or less is particularly preferable.

本発明に係る低置換度ヒドロキシプロピルセルロースの90%積算粒子径は、200μm以下、好ましくは150μm以下、より好ましくは70μm以上130μm以下である。90%積算粒子径が200μmを超えると服用感が悪化するため好ましくない。  The 90% cumulative particle size of the low-substituted hydroxypropylcellulose according to the present invention is 200 μm or less, preferably 150 μm or less, more preferably 70 μm or more and 130 μm or less. If the 90% cumulative particle size exceeds 200 μm, the feeling of dosing deteriorates, which is not preferable.

本発明に係るメマンチン塩酸塩含有口腔内崩壊錠は、低置換度ヒドロキシプロピルセルロース以外にも、種々の添加剤を含有しても良い。添加剤としては、例えば、賦形剤、崩壊剤、結合剤、マスキング剤、被覆剤、着色剤、甘味剤、滑沢剤などが挙げられる。  The memantine hydrochloride-containing orally disintegrating tablet according to the present invention may contain various additives in addition to the low-substituted hydroxypropylcellulose. Examples of the additive include an excipient, a disintegrant, a binder, a masking agent, a coating agent, a coloring agent, a sweetening agent, and a lubricant.

(賦形剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、賦形剤は口当たりなどを考慮すると水溶性もしくは水親和性のものが好ましい。例えば、マンニトール、エリスリトール、ソルビトールおよびキシリトールなどの糖アルコール、トレハロース、シクロデキストリン、トウモロコシデンプン、ショ糖、結晶セルロース、無水リン酸水素カルシウム、炭酸カルシウムなどを単体又は適宜組み合わせて使用することができる。本発明においては糖アルコールが好ましく、マンニトールが特に好ましい。
(Excipient)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, the excipient is preferably water-soluble or water-affinity considering the mouthfeel and the like. For example, sugar alcohols such as mannitol, erythritol, sorbitol and xylitol, trehalose, cyclodextrin, corn starch, sucrose, crystalline cellulose, anhydrous calcium hydrogen phosphate, calcium carbonate and the like can be used alone or in appropriate combination. In the present invention, sugar alcohol is preferred, and mannitol is particularly preferred.

(崩壊剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、崩壊剤は、例えば、低置換度ヒドロキシプロピルセルロース、クロスポビドン、カルメロースカルシウム、カルメロースナトリウム、クロスカルメロースナトリウム、カルメロース、各種デンプン類等から選択することができる。これらの崩壊剤は、単独又は二種以上組み合わせて使用できる。本発明においては、低置換度ヒドロキシプロピルセルロース、クロスポビドンおよびカルメロースカルシウムが好ましい。低置換度ヒドロキシプロピルセルロースは、良好な口腔内崩壊性、さらに高湿度環境下での保存後も良好な硬度を付与する崩壊剤として最も好適である。
(Disintegrant)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, the disintegrant is, for example, from low-substituted hydroxypropylcellulose, crospovidone, carmellose calcium, carmellose sodium, croscarmellose sodium, carmellose, various starches, etc. You can choose. These disintegrants can be used alone or in combination of two or more. In the present invention, low-substituted hydroxypropylcellulose, crospovidone and carmellose calcium are preferred. Low-substituted hydroxypropylcellulose is most suitable as a disintegrating agent that imparts good disintegration property in the oral cavity and further provides good hardness even after storage in a high humidity environment.

(結合剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、結合剤は、例えば、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ポリビニルアルコール、マクロゴール及び上記に賦形剤として示した化合物等から選択することができる。これらの結合剤は、単体または適宜組み合わせて使用することができる。本発明においてはヒドロキシプロピルセルロースが好ましい。
(Binder)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, the binder is selected from, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, macrogol, and the compounds shown above as excipients. be able to. These binders can be used alone or in appropriate combination. In the present invention, hydroxypropylcellulose is preferred.

(マスキング剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、メマンチン塩酸塩の粉末またはメマンチン塩酸塩を含有する顆粒に、苦味を軽減するマスキング剤として、例えば、pH非依存型水不溶性ポリマー及び/またはpH依存型水不溶性ポリマーを用いて造粒又は被覆することができる。pH非依存型水不溶性ポリマーの例としては、エチルセルロース、アミノアルキルメタクリレートコポリマーRSが挙げられ、pH依存型水不溶性ポリマーの例としては、メタクリル酸コポリマー(L、LD、S)、アミノアルキルメタクリレートコポリマーE、ポリビニルアセタールジエチルアミノアセテートが挙げられる。これらのマスキング剤は、単体または適宜組み合わせて使用することができるが、これらに限定されるものではない。本発明においてはメタクリル酸コポリマーLDが好ましい。また、マスキング剤に可塑剤を配合して用いることが好ましい。
(Masking agent)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, a memantine hydrochloride powder or a granule containing memantine hydrochloride is used as a masking agent for reducing bitterness, for example, a pH-independent water-insoluble polymer and / or pH. Dependent water-insoluble polymers can be used to granulate or coat. Examples of the pH-independent water-insoluble polymer include ethyl cellulose and aminoalkyl methacrylate copolymer RS. Examples of the pH-dependent water-insoluble polymer include methacrylic acid copolymer (L, LD, S), aminoalkyl methacrylate copolymer E. And polyvinyl acetal diethylaminoacetate. These masking agents can be used alone or in appropriate combination, but are not limited thereto. In the present invention, methacrylic acid copolymer LD is preferred. Moreover, it is preferable to mix and use a plasticizer for a masking agent.

(可塑剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、メマンチン塩酸塩の粉末またはメマンチン塩酸塩を含有する顆粒に、苦味を軽減するマスキング剤に配合する可塑剤は、例えば、クエン酸トリエチル、マクロゴール、ポリソルベート80、トリアセチン、モノステアリン酸グリセリン等から選択することができる。これらの可塑剤は単体または適宜組み合わせて使用することができる。本発明においてはクエン酸トリエチルが好ましい。
(Plasticizer)
In the orally disintegrating tablet containing memantine hydrochloride according to the present invention, the plasticizer blended in the masking agent for reducing bitterness in the granule containing memantine hydrochloride powder or memantine hydrochloride includes, for example, triethyl citrate, macrogol , Polysorbate 80, triacetin, glyceryl monostearate and the like. These plasticizers can be used alone or in appropriate combination. In the present invention, triethyl citrate is preferred.

(被覆剤)
本発明に係るメマンチン塩酸塩の粉末又はメマンチン塩酸塩を含有する顆粒は、成型性と崩壊性を高めるため、糖アルコールで被覆することもできる。糖アルコールとしては、例えばマンニトール、エリスリトール、ソルビトール、キシリトールなどを単体又は適宜組み合わせて使用することができるが、特にマンニトールが好ましい。
(Coating agent)
The memantine hydrochloride powder or granule containing memantine hydrochloride according to the present invention can be coated with a sugar alcohol in order to improve moldability and disintegration. As the sugar alcohol, for example, mannitol, erythritol, sorbitol, xylitol and the like can be used alone or in appropriate combination, and mannitol is particularly preferable.

(着色剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、着色剤は、例えば、黄色三二酸化鉄、三二酸化鉄、黒酸化鉄、食用黄色5号、食用黄色5号アルミニウムレーキ、リボフラビン等から選択することができる。これらの着色剤は、単体または適宜組み合わせて使用することができる。
(Coloring agent)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, the colorant is selected from, for example, yellow ferric oxide, ferric oxide, black iron oxide, edible yellow No. 5, edible yellow No. 5 aluminum lake, riboflavin and the like. be able to. These colorants can be used alone or in appropriate combination.

(甘味剤)
本発明に係るメマンチン酸塩酸含有口腔内崩壊錠において、甘味剤を用いることも可能であり、例えば、スクラロース、サッカリン、サッカリンナトリウム、アスパルテーム、ステビオシド、還元麦芽糖水飴などを挙げることができる。本発明においてはアスパルテームが好ましい。
(Sweetener)
In the memantic acid-containing orally disintegrating tablet according to the present invention, a sweetening agent can be used, and examples thereof include sucralose, saccharin, sodium saccharin, aspartame, stevioside, and reduced maltose starch syrup. In the present invention, aspartame is preferred.

(滑沢剤)
本発明に係るメマンチン塩酸塩含有口腔内崩壊錠において、滑沢剤は、例えば、ステアリン酸マグネシウム、ステアリン酸、ステアリン酸カルシウム、軽質無水ケイ酸、フマル酸ステアリルナトリウム、タルク、水素添加植物油、マイクロクリスタリンワックス、ショ糖脂肪酸エステル、ポリエチレングリコール等から選択することができる。これらの滑沢剤は、単体または適宜組み合わせて使用することができる。本発明においてはステアリン酸マグネシウムおよびタルクが好ましい。
(lubricant)
In the memantine hydrochloride-containing orally disintegrating tablet according to the present invention, the lubricant includes, for example, magnesium stearate, stearic acid, calcium stearate, light anhydrous silicic acid, sodium stearyl fumarate, talc, hydrogenated vegetable oil, microcrystalline wax. , Sucrose fatty acid ester, polyethylene glycol and the like. These lubricants can be used alone or in appropriate combination. In the present invention, magnesium stearate and talc are preferred.

本発明において、さらに、その他の添加剤として、例えば、甘味剤以外の矯味剤、香料、流動化剤、帯電防止剤、界面活性剤、湿潤剤、充填剤、増量剤、吸着剤、防湿剤、抗酸化剤、保存剤(例えば防腐剤)、緩衝剤などを用いることもできる。  In the present invention, as other additives, for example, flavoring agents other than sweeteners, fragrances, fluidizing agents, antistatic agents, surfactants, wetting agents, fillers, extenders, adsorbents, moisture-proofing agents, Antioxidants, preservatives (for example, preservatives), buffers and the like can also be used.

以上説明したように、本発明に係るメマンチン塩酸塩含有口腔内崩壊錠は、メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含む顆粒に、任意で糖アルコールを被覆した後に、低置換度ヒドロキシプロピルセルロースを添加し圧縮成型することにより得られる。このようにして得られたメマンチン塩酸塩含有口腔内崩壊錠は、適度な硬度と口腔内での良好な崩壊性、さらに加湿条件下での保存後も良好な硬度と良好な口腔内崩壊性を兼ね備える。また、本発明によると、特殊な生産設備を設けることなく、一般的な製造設備にて製造可能な製造方法を提供することができる。  As described above, the memantine hydrochloride-containing orally disintegrating tablet according to the present invention comprises a memantine hydrochloride powder or a granule containing memantine hydrochloride, optionally coated with a sugar alcohol, and then a low-substituted hydroxypropylcellulose. It is obtained by adding and compression molding. The memantine hydrochloride-containing orally disintegrating tablet thus obtained has moderate hardness and good disintegration property in the oral cavity, and also has good hardness and good oral disintegration property after storage under humidified conditions. Have both. Moreover, according to this invention, the manufacturing method which can be manufactured with a general manufacturing facility can be provided, without providing a special production facility.

次に実施例を挙げて、本発明を詳しく説明するが、本発明はこれに限られるものではない。  EXAMPLES Next, although an Example is given and this invention is demonstrated in detail, this invention is not limited to this.

実施例1
(メマンチン塩酸塩10mg含有口腔内崩壊錠)
メマンチン塩酸塩800.0g、D−マンニトール(ロケット製)1840.0g、カルメロースカルシウム(五徳薬品製)176.0gを流動層造粒機(フロイント製、FLO‐5M)に投入し、ヒドロキシプロピルセルロース(日本曹達製)88.0gを精製水2845.3gに溶解した液を噴霧後、乾燥することで造粒物を得た。得られた造粒物2904.0gを流動層造粒機(フロイント製、FLO‐5M)に投入しコーティング液10562.7g(メタクリル酸コポリマーLD(エボニック製、オイドラギットL30D−55)3866.7g、クエン酸トリエチル(森村商事製)120.0g、タルク(勝光山鉱業所製)576.0g、精製水6000.0g)を噴霧し、乾燥することで薬物含有コーティング顆粒を得た。薬物含有コーティング顆粒4760.0gを流動層造粒機に投入し、D−マンニトール720.0gを精製水6480.0gに溶解した液を噴霧後、乾燥することで薬物含有粒子被覆顆粒を得た。薬物含有粒子被覆顆粒137.0g、D−マンニトール(フロイント製、グラニュトールS)113.8g、クロスポビドン(BASF製、コリドンCL−F)8.4g、低置換度ヒドロキシプロピルセルロース(信越化学工業製、NBD−022)8.4g、アスパルテーム(味の素製)9.6g、香料(高砂香料工業製)0.2gを3分間混合した。得られた混合物にステアリン酸マグネシウム(太平化学産業製)2.8gを加え1分間混合後、ロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径7.5φ、錠厚3.5mm、1錠あたりの質量140mg)を作製した。
Example 1
(Memantine hydrochloride 10mg containing orally disintegrating tablets)
Memantine hydrochloride 800.0 g, D-mannitol (Rocket) 1840.0 g, Carmellose calcium (Gotoku Pharmaceutical) 176.0 g were charged into a fluidized bed granulator (Freund, FLO-5M), and hydroxypropylcellulose. A granulated product was obtained by spraying a solution obtained by dissolving 88.0 g (manufactured by Nippon Soda) in 2845.3 g of purified water and then drying. 2904.0 g of the obtained granulated product was put into a fluidized bed granulator (Freund, FLO-5M), and coating liquid 10562.7 g (methacrylic acid copolymer LD (Evonik, Eudragit L30D-55) 3866.7 g, 120.0 g of triethyl acid (manufactured by Morimura Shoji Co., Ltd.), 576.0 g of talc (manufactured by Katsumiyama Mining), 6000.0 g of purified water) were sprayed and dried to obtain drug-containing coated granules. 4760.0 g of drug-containing coated granules were charged into a fluidized bed granulator, and a solution obtained by dissolving 720.0 g of D-mannitol in 6480.0 g of purified water was sprayed and dried to obtain drug-containing particle-coated granules. Drug-containing particle-coated granules 137.0 g, D-mannitol (Freund, Granitol S) 113.8 g, crospovidone (BASF, Kollidon CL-F) 8.4 g, low-substituted hydroxypropylcellulose (Shin-Etsu Chemical) , NBD-022) 8.4 g, Aspartame (Ajinomoto Co., Ltd.) 9.6 g, and Fragrance (Takasago Fragrance Co., Ltd.) 0.2 g were mixed for 3 minutes. 2.8 g of magnesium stearate (manufactured by Taihei Chemical Sangyo) was added to the resulting mixture and mixed for 1 minute, followed by orally disintegrating tablets (tablet conditions: tablet diameter 7.5φ, tablet thickness 3.5 mm) using a rotary tableting machine. A mass of 140 mg per tablet) was prepared.

実施例2
(メマンチン塩酸塩20mg含有口腔内崩壊錠)
メマンチン塩酸塩100.0g、D−マンニトール(ロケット製)230.0g、カルメロースカルシウム(五徳薬品製)22.0gを流動層造粒機(パウレック製、MP−01)に投入し、ヒドロキシプロピルセルロース(日本曹達製)11.0gを精製水356.0gに溶解した液を噴霧後、乾燥することで造粒物を得た。得られた造粒物363.0gを流動層造粒機(パウレック製、MP−01)に投入しコーティング液1320.3g(メタクリル酸コポリマーLD(エボニック製、オイドラギットL30D−55)483.3g、クエン酸トリエチル(森村商事製)15.0g、タルク(勝光山鉱業所製)72.0g、精製水750.0g)を噴霧し、乾燥することで薬物含有コーティング顆粒を得た。薬物含有コーティング顆粒595.0gを流動層造粒機に投入し、D−マンニトール119.0gを精製水1071.0gに溶解した液を噴霧後、乾燥することで薬物含有粒子被覆顆粒を得た。薬物含有粒子被覆顆粒142.8g、D−マンニトール(フロイント製、グラニュトールS)111.2g、クロスポビドン(BASF製、コリドンCL−F)8.2g、低置換度ヒドロキシプロピルセルロース(信越化学工業製、NBD−022)5.4g、アスパルテーム(味の素製)9.6g、香料(高砂香料工業製)0.2gを3分間混合した。得られた混合物にステアリン酸マグネシウム(太平化学産業製)2.8gを加え1分間混合後、ロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径9.0φ、錠厚4.8mm、1錠あたりの質量280mg)を作製した。
Example 2
(Memantine hydrochloride 20 mg containing orally disintegrating tablets)
100.0 g of memantine hydrochloride, 230.0 g of D-mannitol (manufactured by Rocket) and 22.0 g of carmellose calcium (manufactured by Gotoku Pharmaceutical) were charged into a fluidized bed granulator (manufactured by Paulek, MP-01), and hydroxypropylcellulose A granulated product was obtained by spraying a solution obtained by dissolving 11.0 g (manufactured by Nippon Soda) in 356.0 g of purified water and then drying. 363.0 g of the obtained granulated product was charged into a fluidized bed granulator (manufactured by Paul Wrec, MP-01), and coating solution 1320.3 g (methacrylic acid copolymer LD (Evonik, Eudragit L30D-55) 483.3 g, 35.0 g of triethyl acid (manufactured by Morimura Shoji), 72.0 g of talc (manufactured by Katsumiyama Mining), 750.0 g of purified water) were sprayed and dried to obtain drug-containing coated granules. 595.0 g of the drug-containing coated granule was put into a fluidized bed granulator, and a solution obtained by dissolving 119.0 g of D-mannitol in 1071.0 g of purified water was sprayed and dried to obtain a drug-containing particle-coated granule. 142.8 g of drug-containing particle-coated granules, 111.2 g of D-mannitol (Freund, Granitol S), 8.2 g of crospovidone (BASF, Kollidon CL-F), low-substituted hydroxypropyl cellulose (manufactured by Shin-Etsu Chemical) , NBD-022) 5.4 g, Aspartame (Ajinomoto Co., Ltd.) 9.6 g, and Fragrance (Takasago Fragrance Co., Ltd.) 0.2 g were mixed for 3 minutes. 2.8 g of magnesium stearate (manufactured by Taihei Chemical Sangyo) was added to the resulting mixture and mixed for 1 minute, followed by orally disintegrating tablet (tablet conditions: tablet diameter 9.0φ, tablet thickness 4.8 mm) using a rotary tableting machine. A mass per tablet (280 mg) was prepared.

実施例3
(メマンチン塩酸塩10mg含有口腔内崩壊錠)
実施例1に記載の薬物含有粒子被覆顆粒137.0g、低置換度ヒドロキシプロピルセルロースを含有する乾式直打用賦形剤(信越化学工業製、SmartEx(登録商標) QD−50)122.2g、クロスポビドン(BASF製、コリドンCL−F)8.4g、アスパルテーム(味の素製)9.6g、香料(高砂香料工業製)0.2gを3分間混合した。得られた混合物にステアリン酸マグネシウム(太平化学産業製)2.8gを加え1分間混合後、得られた打錠用顆粒からロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径7.5φ、錠厚3.5mm、1錠あたりの質量140mg)を作製した。
Example 3
(Memantine hydrochloride 10mg containing orally disintegrating tablets)
137.0 g of drug-containing particle-coated granules described in Example 1 and 122.2 g of dry direct-implanting excipient (Shin-Etsu Chemical Co., Ltd., SmartEx (registered trademark) QD-50) containing low-substituted hydroxypropylcellulose. 8.4 g of crospovidone (BASF, Kollidon CL-F), 9.6 g of aspartame (manufactured by Ajinomoto), and 0.2 g of fragrance (manufactured by Takasago Kagaku Kogyo) were mixed for 3 minutes. 2.8 g of magnesium stearate (manufactured by Taihei Chemical Industry) was added to the resulting mixture and mixed for 1 minute, and then the tableting granules obtained were orally disintegrated with a rotary tableting machine (tablet conditions: tablet diameter 7). .5φ, tablet thickness 3.5 mm, mass per tablet 140 mg).

実施例4
(メマンチン塩酸塩20mg含有口腔内崩壊錠)
実施例3で作製した打錠用顆粒を用いて、ロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径9.0φ、錠厚4.8mm、1錠あたりの質量280mg)を作製した。
Example 4
(Memantine hydrochloride 20 mg containing orally disintegrating tablets)
Orally disintegrating tablets (tablet conditions: tablet diameter 9.0φ, tablet thickness 4.8 mm, mass per tablet 280 mg) using a tableting granule prepared in Example 3 using a rotary tableting machine did.

比較例1
(メマンチン塩酸塩10mg含有口腔内崩壊錠)
実施例1に記載の薬物含有粒子被覆顆粒137.0g、D−マンニトール(フロイント製、グラニュトールS)121.4g、クロスポビドン(BASF製、コリドンCL−F)8.4g、アスパルテーム(味の素製)9.6g、香料(高砂香料工業製)0.2gを3分間混合した。得られた混合物にステアリン酸マグネシウム(太平化学産業製)3.6gを加え1分間混合後、ロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径7.5φ、錠厚3.5mm、1錠あたりの質量140mg)を作製した。
Comparative Example 1
(Memantine hydrochloride 10mg containing orally disintegrating tablets)
137.0 g of drug-containing particle-coated granules described in Example 1, D-mannitol (Freund, Granitol S) 121.4 g, crospovidone (BASF, Kollidon CL-F) 8.4 g, aspartame (Ajinomoto) 9.6 g and fragrance | flavor (product made from Takasago fragrance industry) 0.2g were mixed for 3 minutes. To the obtained mixture, 3.6 g of magnesium stearate (manufactured by Taihei Chemical Industry) was added and mixed for 1 minute, and then orally disintegrating tablet (tablet conditions: tablet diameter 7.5φ, tablet thickness 3.5 mm) using a rotary tableting machine. A mass of 140 mg per tablet) was prepared.

比較例2
(メマンチン塩酸塩10mg含有口腔内崩壊錠)
実施例1に記載の薬物含有粒子被覆顆粒137.0g、D−マンニトール(フロイント製、グラニュトールS)117.8g、結晶セルロース(旭化成製、セオラスPH−302)8.4g、クロスポビドン(BASF製、コリドンCL−F)8.4g、アスパルテーム(味の素製)4.8g、香料(高砂香料工業製)0.2gを3分間混合した。得られた混合物にステアリン酸マグネシウム(太平化学産業製)3.6gを加え1分間混合後、ロータリー打錠機にて口腔内崩壊錠(打錠条件:錠剤径7.5φ、錠厚3.5mm、1錠あたりの質量140mg)を作製した。
Comparative Example 2
(Memantine hydrochloride 10mg containing orally disintegrating tablets)
137.0 g of drug-containing particle-coated granules described in Example 1, D-mannitol (Freund, Granitol S) 117.8 g, crystalline cellulose (Asahi Kasei, Theolas PH-302) 8.4 g, crospovidone (BASF) , Kollidon CL-F) 8.4 g, aspartame (Ajinomoto Co., Ltd.) 4.8 g, and fragrance (Takasago Fragrance Co., Ltd.) 0.2 g were mixed for 3 minutes. To the obtained mixture, 3.6 g of magnesium stearate (manufactured by Taihei Chemical Industry) was added and mixed for 1 minute, and then orally disintegrating tablet (tablet conditions: tablet diameter 7.5φ, tablet thickness 3.5 mm) using a rotary tableting machine. A mass of 140 mg per tablet) was prepared.

実施例1から実施例4、比較例1と比較例2及び市販製剤(比較例3、メマリー(登録商標)OD錠10mg)の錠剤について、加湿前、及び25℃相対湿度75%の条件下で3日間加湿後に、錠剤硬度(平均硬度)及び崩壊時間を測定した。得られた結果を表1に示す。  About Example 1 to Example 4, Comparative Example 1 and Comparative Example 2, and a tablet of a commercially available formulation (Comparative Example 3, Memary (registered trademark) OD tablet 10 mg) under humidification conditions and under conditions of 25% relative humidity 75% After humidification for 3 days, tablet hardness (average hardness) and disintegration time were measured. The obtained results are shown in Table 1.

Figure 2019019113
Figure 2019019113

メマンチン塩酸塩を含有する顆粒に、低置換ヒドロキシプロピルセルロースを添加し圧縮成型した実施例1から4の錠剤は、良好な硬度(加湿前硬度;4.4〜8.7Kgf)ならびに良好な口腔内崩壊性(加湿前崩壊時間;12〜20秒)を示した。さらに、加湿保存後にも良好な硬度(加湿後硬度;2.3〜5.6Kgf)及び良好な口腔内崩壊性(加湿後崩壊時間;9〜18秒)を保持していた。低置換度ヒドロキシプロピルセルロースを含有しない比較例1〜3の口腔内崩壊錠では加湿保存後の硬度が大きく低下したことと比較して、本発明が奏する効果は顕著に優れたものである。  The tablets of Examples 1 to 4, which were compression-molded by adding low-substituted hydroxypropylcellulose to granules containing memantine hydrochloride, had good hardness (hardness before humidification; 4.4 to 8.7 kgf) and good oral cavity. Disintegration property (disintegration time before humidification; 12 to 20 seconds) was exhibited. Furthermore, after humidification preservation | save, favorable hardness (hardness after humidification; 2.3-5.6Kgf) and favorable oral disintegration (disintegration time after humidification; 9-18 seconds) were maintained. In the orally disintegrating tablets of Comparative Examples 1 to 3 that do not contain low-substituted hydroxypropylcellulose, the effect of the present invention is remarkably excellent as compared with the fact that the hardness after humid storage is greatly reduced.

本発明により、加湿前のみならず加湿保存後であっても良好な硬度と良好な口腔内崩壊性を併せ持った、ユーザービリティに優れるメマンチン塩酸塩含有口腔内崩壊錠が提供される。また、本発明によれば、特殊な生産設備を設けることなく、一般的な製造設備にて製造可能であり、容易に大量生産しうるメマンチン塩酸塩含有口腔内崩壊錠が提供される。  According to the present invention, there is provided a memantine hydrochloride-containing orally disintegrating tablet excellent in usability, having both good hardness and good oral disintegration property not only before humidification but also after humidification storage. Moreover, according to this invention, the memantine hydrochloride containing orally disintegrating tablet which can be manufactured with a general manufacturing facility and can be mass-produced easily without providing a special production facility is provided.

Claims (7)

メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含有する顆粒、及び低置換度ヒドロキシプロピルセルロースを含有する、メマンチン塩酸塩含有口腔内崩壊錠。  A memantine hydrochloride-containing orally disintegrating tablet comprising memantine hydrochloride powder or granules containing memantine hydrochloride and low-substituted hydroxypropylcellulose. メマンチン塩酸塩の粉末又はメマンチン塩酸塩を含有する顆粒が、糖アルコールで被覆されている、請求項1に記載のメマンチン塩酸塩含有口腔内崩壊錠。  The memantine hydrochloride-containing orally disintegrating tablet according to claim 1, wherein memantine hydrochloride powder or granules containing memantine hydrochloride are coated with sugar alcohol. 錠剤の全重量に対して、メマンチン塩酸塩の含量が2.0重量%以上10.0重量%以下である、請求項1又は2に記載のメマンチン塩酸塩含有口腔内崩壊錠。  The memantine hydrochloride-containing orally disintegrating tablet according to claim 1 or 2, wherein the memantine hydrochloride content is 2.0 wt% or more and 10.0 wt% or less based on the total weight of the tablet. 錠剤の全重量に対して、低置換度ヒドロキシプロピルセルロースの含量が0.5重量%以上15.0重量%以下である、請求項1から3のいずれか1項に記載のメマンチン塩酸塩含有口腔内崩壊錠。  The memantine hydrochloride-containing oral cavity according to any one of claims 1 to 3, wherein the content of low-substituted hydroxypropylcellulose is 0.5% by weight or more and 15.0% by weight or less based on the total weight of the tablet. Inner disintegrating tablet. 糖アルコールがマンニトールである、請求項2から4のいずれか1項に記載のメマンチン塩酸塩含有口腔内崩壊錠。  The memantine hydrochloride-containing orally disintegrating tablet according to any one of claims 2 to 4, wherein the sugar alcohol is mannitol. 25℃、相対湿度75%に3日間保存後の錠剤硬度が2.0Kgf以上である、請求項1から5のいずれか1項に記載のメマンチン塩酸塩含有口腔内崩壊錠。  The memantine hydrochloride-containing orally disintegrating tablet according to any one of claims 1 to 5, wherein the tablet hardness after storage for 3 days at 25 ° C and 75% relative humidity is 2.0 kgf or more. 流動層造粒法によって製造することを特徴とする、請求項1から6のいずれか1項に記載のメマンチン塩酸塩含有口腔内崩壊錠の製造方法。  The method for producing a memantine hydrochloride-containing orally disintegrating tablet according to any one of claims 1 to 6, which is produced by a fluidized bed granulation method.
JP2017147187A 2017-07-11 2017-07-11 Orally disintegrating tablet containing memantine hydrochloride Active JP7198575B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017147187A JP7198575B2 (en) 2017-07-11 2017-07-11 Orally disintegrating tablet containing memantine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017147187A JP7198575B2 (en) 2017-07-11 2017-07-11 Orally disintegrating tablet containing memantine hydrochloride

Publications (2)

Publication Number Publication Date
JP2019019113A true JP2019019113A (en) 2019-02-07
JP7198575B2 JP7198575B2 (en) 2023-01-04

Family

ID=65354897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017147187A Active JP7198575B2 (en) 2017-07-11 2017-07-11 Orally disintegrating tablet containing memantine hydrochloride

Country Status (1)

Country Link
JP (1) JP7198575B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535644A (en) * 2019-04-12 2022-08-10 ラ ファーマテック インコーポレイテッド Pharmaceutical compositions and methods for treating psychiatric, behavioral and cognitive disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103731A (en) * 1998-07-28 2000-04-11 Takeda Chem Ind Ltd Rapid disintegrative solid preparation
CN1709229A (en) * 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 Memantine hydrochloride orally disintegrating tablet and its preparing method
WO2013161823A1 (en) * 2012-04-24 2013-10-31 第一三共株式会社 Orally disintegrating tablet and method for producing same
JP2017052754A (en) * 2015-09-07 2017-03-16 共和薬品工業株式会社 Method for producing orally disintegrating tablet, and granules used for the same
JP2018127446A (en) * 2017-02-10 2018-08-16 大原薬品工業株式会社 Pharmaceutical preparation containing memantine hydrochloride with improved chemical stability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103731A (en) * 1998-07-28 2000-04-11 Takeda Chem Ind Ltd Rapid disintegrative solid preparation
CN1709229A (en) * 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 Memantine hydrochloride orally disintegrating tablet and its preparing method
WO2013161823A1 (en) * 2012-04-24 2013-10-31 第一三共株式会社 Orally disintegrating tablet and method for producing same
JP2017052754A (en) * 2015-09-07 2017-03-16 共和薬品工業株式会社 Method for producing orally disintegrating tablet, and granules used for the same
JP2018127446A (en) * 2017-02-10 2018-08-16 大原薬品工業株式会社 Pharmaceutical preparation containing memantine hydrochloride with improved chemical stability

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535644A (en) * 2019-04-12 2022-08-10 ラ ファーマテック インコーポレイテッド Pharmaceutical compositions and methods for treating psychiatric, behavioral and cognitive disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
JP7365426B2 (en) 2019-04-12 2023-10-19 ラ ファーマテック インコーポレイテッド Pharmaceutical compositions and methods for treating mental, behavioral, and cognitive disorders
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Also Published As

Publication number Publication date
JP7198575B2 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
JP6092936B2 (en) Method for producing orally disintegrating tablets
JP5409382B2 (en) Orally disintegrating tablets
ES2393640T3 (en) Orodisintegrable tablets
JP5296456B2 (en) Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
US9278063B2 (en) Press-coated orally-disintegrating tablets
JP6919119B2 (en) A compressed solid pharmaceutical composition containing a γ-aminobutyric acid derivative substituted at the 3-position.
JP7198575B2 (en) Orally disintegrating tablet containing memantine hydrochloride
JP7036856B2 (en) Orally disintegrating tablet
JP2017141299A (en) Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2018145206A (en) Oral disintegrating tablet with improved chemical stability and feeling of ingestion of the raw drug
JP5978335B2 (en) Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP2005139085A (en) Granule
JP2019019125A (en) Orally disintegrating tablet and method for producing the same
JP5575119B2 (en) Orally disintegrating tablets
JP7148319B2 (en) Orally disintegrating tablet containing prasugrel
JP6151413B2 (en) Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP5714652B2 (en) Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP7023186B2 (en) Orally disintegrating tablets containing dementia treatment
KR20180098282A (en) Compression-molded preparation
JP7308022B2 (en) Orally disintegrating tablet with suppressed bitterness of fast-dissolving drug
JP6150564B2 (en) Orally rapidly disintegrating tablets
CN115803020A (en) Orally disintegrating tablet containing milobalin besylate
JP2019203031A (en) Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
WO2019098327A1 (en) Orally disintegrating tablet having suppressed bitterness of fast dissolving drug
JP2018168185A (en) Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221219

R150 Certificate of patent or registration of utility model

Ref document number: 7198575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150